Clozapine is widely considered the most effective medication for treatment-resistant schizophrenia, but fears about a dangerous drop in white blood cells have long kept it from wider use. A new large-scale study from Taiwan offers some of the clearest real-world evidence yet about when that risk is highest and who is most vulnerable.
According to research published in the Lancet Regional Health Western Pacific, the study drew on data from Taiwan's National Health Insurance database covering the years 2014 through 2023. Researchers identified 12,810 new clozapine users and tracked them for cases of neutropenia, a condition in which the body's neutrophil count falls to levels that can leave patients unable to fight infections.
The findings showed that isolated minor neutropenia occurred at a rate of 10.5 per 1,000 person-years. Serious neutropenia that led doctors to stop the medication entirely occurred at just 1.7 per 1,000 person-years. Those numbers suggest the most feared outcome is relatively uncommon, at least at a population level.
The timing of risk was one of the study's most concrete findings. Using a statistical technique called joinpoint regression, researchers identified early inflection points in the risk curves. Serious neutropenia without treatment cessation peaked earliest, around week 6. Isolated minor cases peaked around week 14, and serious cases leading to drug discontinuation around week 15. In practical terms, the risk was concentrated in the first few months after starting the drug.
Two patient-level factors were consistently linked to higher risk across all neutropenia categories: older age and a lower white blood cell count at the start of treatment. Concomitant medications also played a role, though their associations were generally stronger for minor events than for serious ones.
The researchers also examined patients who restarted clozapine after a gap of at least 42 days. That group showed risk patterns similar to new users, a finding relevant for clinicians deciding whether it is safe to resume the drug after an interruption.
The study's authors said the findings support risk-informed monitoring strategies, rather than blanket caution. Clozapine's use has been restricted in many settings because of mandatory blood monitoring requirements, which create burdens for patients and clinicians. This research suggests that the window of highest risk is identifiable and that patients with better baseline blood counts and younger age may face meaningfully lower danger.
The study was funded by the National Health Research Institutes in Taiwan and is among the largest real-world analyses of clozapine-associated neutropenia conducted to date.
